Pyxis Oncology, Inc. 8-K

What Happened
Pyxis Oncology, Inc. announced its financial results for the quarter ended March 31, 2026 and provided a corporate update via a press release dated May 14, 2026. The press release was furnished as Exhibit 99.1 to the Form 8-K filed with the SEC on May 14, 2026.

Key Details

• Filed Form 8-K on May 14, 2026 reporting results of operations and financial condition (Item 2.02).
• Press release covering the quarter ended March 31, 2026 is included as Exhibit 99.1.
• The report also includes Exhibit 104 (cover page interactive data / Inline XBRL).
• The filing was signed by Jitendra Wadhane, Principal Financial and Accounting Officer.

Why It Matters
This filing notifies investors that Pyxis has released its quarterly earnings and a corporate update; those details (revenue, earnings, guidance, or operational highlights) are contained in the attached press release. Retail investors should read Exhibit 99.1 to see the specific financial results and any management commentary that could affect the company’s near-term outlook or stock performance.